Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

Hyperpolarized 129Xe MRIMRIPulmonary Function TestingfILDFibrotic Interstitial Lung DiseaseAntifibrotic TherapyTherapeutic Response

Outcome Measures

Primary Outcomes (1)

Measure 129Xe imaging ventilation defects qualitatively and quantitatively in participants diagnosed with fibrotic interstitial lung disease.
The extent and timing of clinical and imaging-based physiologic changes following treatment initiation for fibrotic interstitial lung disease will be assessed using conventional assessments and advanced pulmonary imaging (MRI and CT). Measurements will include 129Xe compartment-specific physiologic abnormalities and ventilation defect percent (VDP), Pulmonary Function Test (PFT) including Forced Vital Capacity (FVC), Total Lung Capacity (TLC) and Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO), Six-Minute Walk Test (6MWT), symptom scores from St George's Respiratory Questionnaire (SGRQ-I) and King's Brief Interstitial Lung Disease (KBILD) questionnaires, CT parenchyma/airway/vessel morphology.
3 visits; Visit 1 at baseline, before treatment initiation. Visit 2 at 24 weeks post-treatment initiation. Visit 3 at 48 weeks post treatment initiation. Each visit will include MRI and CT imaging, Blood test, PFT, questionnaires and 6MWT.

Secondary Outcomes (1)

Determine the relationships between clinical and imaging response to therapy and generate predictive models for their achievement at 1-year using baseline markers and their changes at 24 weeks.
From baseline to 1 year post-therapy initiation.

Study Arms (1)

Fibrotic Interstitial Lung Disease

Other: Hyperpolarized 129Xe MRI

Interventions

Hyperpolarized 129Xe MRIOther

Inhalation of hyperpolarized 129Xe gas followed by breath-hold MRI for ventilation imaging.

Fibrotic Interstitial Lung Disease

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Participants will be adults 18-80 years of age with physician-diagnosed fibrotic interstitial lung disease consistent with 2022 ATS/ERS guidelines and are eligible for antifibrotic therapy. Participants will be referred from respirologists at LHSC London outpatient respirology clinics.

You may qualify if:

Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.

Sponsors & Collaborators

Dr. Grace Parraga
Otherlead

Study Sites (1)

Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre

London, Ontario, N6A 5B7, Canada

Grace Parraga, PhDCONTACT519-931-5265 gparraga@uwo.ca

Andraena K Tilgner, BHSc., RRTCONTACT519-661-2111 ext. 89853 atilgner@uwo.ca

Grace Parraga, PhDPRINCIPAL INVESTIGATOR

Study Officials

Grace E Parraga, PHD
Robarts Research Institute, The University of Western Ontario
PRINCIPAL INVESTIGATOR

Central Study Contacts

Grace E Parraga, PhD

CONTACT

519-931-5265 gparraga@robarts.ca

Andraena K Tilgner, BHSc., RRT

CONTACT

519-661-2111

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 50 Weeks
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

August 20, 2026

First Posted

August 25, 2026

Study Start

November 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

November 2028

Mechanistic 129 Xe MRI Study to Assess Therapeutic Response in Fibrotic Interstitial Lung Disease

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Fibrotic Interstitial Lung Disease

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

Fibrotic Interstitial Lung Disease

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations